LONG-ACTING CONTROLLED-RELEASE SUBCUTANEOUS POLYMER IMPLANT OF PHARMACOLOGICAL PRE-CONCENTRATED SUBSTANCE FOR TREATMENT OF ERECTILE DYSFUNCTION AND BENIGN PROSTATIC HYPERPLASIA Russian patent published in 2024 - IPC A61K31/4985 A61K47/36 A61K47/38 A61K47/44 A61P13/08 A61P15/10 

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine, namely to long-acting subcutaneous polymer implants with controlled release of pharmacological pre-concentrated substance for treatment of erectile dysfunction and benign prostatic hyperplasia. Disclosed is a long-acting controlled-release subcutaneous polymer implant of a pharmacological pre-concentrated substance for the treatment of erectile dysfunction and benign prostatic hyperplasia, which is characterized by the fact that the biodegradable implant contains from 25 to 250 mg of tadalafil in the form of particles homogeneously dispersed in the biodegradable and bioabsorbable polymer matrix, wherein the polymer matrix contains from 1 to 20% of a biodegradable polymer with respect to the weight of tadalafil. Disclosed is a long-acting controlled-release subcutaneous polymer implant of a pharmacological pre-concentrated substance for the treatment of erectile dysfunction and benign prostatic hyperplasia, which is characterized by that the implant is presented in a non-biodegradable form, has a central core formed by a polymer matrix in percentage ratio of 1 to 20% with respect to the weight of drug - 25 to 250 mg of tadalafil, and the core itself is surrounded by a non-degradable polymer membrane.

EFFECT: said group of inventions provides prolonged release of the drug into the bloodstream in low doses, allows minimizing side effects and improving quality of life in patients with erectile dysfunction and benign prostatic hyperplasia.

7 cl, 3 dwg